Low dose injectable contraceptive norethisterone enanthate 20mg monthly - II. Metabolic side effects.
Metabolic effects of a long-acting low dose injectable contraceptive, norethisterone enanthate 20-mg, monthly injections (Neten-20), was tested in 13 women belonging to the low income groups over a period of 1 year. No change was observed in hemoglobin, hematocrit, glucose tolerance, plasma lipids, iron, calcium, or serum glutamate-oxaloacetate transaminase after treatment. Marginal rise in albumin and fall in some globulin fractions was observed. The slight fall seen in serum alkaline phosphatase could be attributed to a change in lactation status. Vitamin A, pyridoxine and riboflavin status were not altered. A peculiar aberration in the tryptophan-niacin pathway as indicated by rise in kynurenic acid excretion after tryptophan load was observed. This could be corrected by multivitamin therapy. These data suggest that the use of Neten-20 for one year does not lead to adverse metabolic effects analogous to those seen with combination type oral contraceptives.
D000469:Alkaline Phosphatase / Q000378:metabolism; D003271:Contraceptive Agents, Female; D004305:Dose-Response Relationship, Drug; D005260:Female; D005916:Globulins / Q000378:metabolism; D005951:Glucose Tolerance Test; D006801:Humans; D007736:Kynurenic Acid / Q000652:urine; D009640:Norethindrone / Q000009:adverse effects / Q000494:pharmacology*; D012257:Riboflavin Deficiency / Q000209:etiology; D012709:Serum Albumin / Q000378:metabolism; D014364:Tryptophan / Q000378:metabolism
D003271:Contraceptive Agents, Female; D005916:Globulins; D012709:Serum Albumin; D014364:Tryptophan; D000469:Alkaline Phosphatase; D007736:Kynurenic Acid; D009640:Norethindrone